Načítá se...
FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy
In December 2019, a novel SARS-CoV-2 coronavirus emerged, causing an outbreak of life-threatening pneumonia in the Hubei province, China, and has now spread worldwide, causing a pandemic. The urgent need to control the disease, combined with the lack of specific and effective treatment modalities, c...
Uloženo v:
| Vydáno v: | Drug Resist Updat |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Published by Elsevier Ltd.
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7362818/ https://ncbi.nlm.nih.gov/pubmed/32717568 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.drup.2020.100719 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|